Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.97 USD
Change Today -0.01 / -0.51%
Volume 76.6K
CLSN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

celsion corp (CLSN) Snapshot

Open
$1.95
Previous Close
$1.98
Day High
$2.09
Day Low
$1.93
52 Week High
04/15/15 - $3.57
52 Week Low
08/24/15 - $1.80
Market Cap
45.4M
Average Volume 10 Days
97.2K
EPS TTM
$-1.29
Shares Outstanding
23.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELSION CORP (CLSN)

celsion corp (CLSN) Related Bloomberg News

View More Bloomberg News

celsion corp (CLSN) Related Businessweek News

No Related Businessweek News Found

celsion corp (CLSN) Details

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

28 Employees
Last Reported Date: 03/12/15
Founded in 1982

celsion corp (CLSN) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $462.4K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $368.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $446.9K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $154.7K
Compensation as of Fiscal Year 2014.

celsion corp (CLSN) Key Developments

Celsion Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Celsion Corporation reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported licensing revenue of $125,000 against $125,000 a year ago. Loss from operations was $5,245,000 against $6,413,000 a year ago. Net loss was $5,675,000 against $6,673,000 a year ago. Net loss per common share basic and diluted was $0.27 against $0.38 a year ago. For the six months, the company reported licensing revenue of $250,000 against $250,000 a year ago. Loss from operations was $11,658,000 against $11,615,000 a year ago. Net loss was $12,680,000 against $12,096,000 a year ago. Net loss per common share basic and diluted was $0.62 against $0.71 a year ago. Net cash used in operations was $11.6 million in the first half of 2015 compared to $9.0 million in the same period last year.

Celsion Corporation Announces Updated Overall Survival Data from HEAT Study of ThermoDox(R) in Primary Liver Cancer

Celsion Corporation announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). As of July 15, 2015, the latest overall survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the HEAT Study patients), treatment with a combination of ThermoDox® and optimized RFA provided an average 58% improvement in OS compared to optimized RFA alone. The Hazard Ratio (HR) at this analysis is 0.63 (95% CI 0.43 – 0.93) with a p-value of 0.0198. Median overall survival for the ThermoDox® group has been reached which translates into a 25.4 month (2.1 year) survival benefit over the optimized RFA group (79 months for the ThermoDox® plus optimized RFA group versus 53.6 months for the optimized RFA only group). In the most recent post-hoc analysis of the HEAT Study, data continued to support and further strengthen ThermoDox®'s potential to significantly improve OS compared to an RFA control in patients with lesions that undergo optimized RFA treatment for 45 minutes or more. Findings from this analysis apply to patients with single HCC lesions (64.4% of the HEAT Study population) from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm), representing a subgroup of 285 patients. Additional findings from this most recent analysis specific to the Chinese cohort of patients with single lesions (74% of the HEAT Study Chinese patient population) showed a 75% improvement (HR = 0.57 with a p-value of 0.08) in OS for the ThermoDox® plus optimized RFA group compared to optimized RFA only group. Patients in the Chinese cohort with single lesions between 3-5 cm showed a doubling of improvement (HR = 0.50 with a p-value of 0.06) in OS when treated with ThermoDox® plus optimized RFA. The Phase III OPTIMA Study is expected to enroll up to 550 patients in up to 75 clinical sites in the United States, Europe, China and Asia Pacific, and will evaluate ThermoDox® in combination with optimized RFA, which will be standardized to a minimum of 45 minutes across all investigators and clinical sites for treating lesions three to seven centimeters, versus standardized RFA alone. The primary endpoint for the trial is Overall Survival, which is supported by post-hoc analysis of data from the Company's 701 patient HEAT Study, where optimized RFA has demonstrated the potential to significantly improve survival when combined with ThermoDox®. The statistical plan calls for two interim efficacy analyses by an independent Data Monitoring Committee (iDMC).

Celsion Corp. to Report Q2, 2015 Results on Aug 10, 2015

Celsion Corp. announced that they will report Q2, 2015 results at 11:00 AM, US Eastern Standard Time on Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLSN:US $1.97 USD -0.01

CLSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Medifocus Inc C$0.05 CAD 0.00
Perseon Corp $0.46 USD +0.04
View Industry Companies
 

Industry Analysis

CLSN

Industry Average

Valuation CLSN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 83.0x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSION CORP, please visit www.celsion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.